GSD Stock Overview
Engages in the development of botanical drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Devonian Health Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.16 |
| 52 Week High | CA$0.35 |
| 52 Week Low | CA$0.075 |
| Beta | 1.38 |
| 1 Month Change | -11.11% |
| 3 Month Change | n/a |
| 1 Year Change | 10.34% |
| 3 Year Change | -72.41% |
| 5 Year Change | -3.03% |
| Change since IPO | -80.00% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Devonian Health Group Inc.'s (CVE:GSD) Prospects As Shares Rocket 33%
Dec 01
Is Devonian Health Group (CVE:GSD) A Risky Investment?
Mar 20Is Devonian Health Group (CVE:GSD) Using Debt In A Risky Way?
Dec 01Is Devonian Health Group (CVE:GSD) Weighed On By Its Debt Load?
Aug 18Does Devonian Health Group (CVE:GSD) Have A Healthy Balance Sheet?
Apr 24Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?
Mar 02Shareholder Returns
| GSD | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -15.8% | -1.1% | -0.5% |
| 1Y | 10.3% | -32.0% | 14.9% |
Return vs Industry: GSD exceeded the Canadian Pharmaceuticals industry which returned -31.4% over the past year.
Return vs Market: GSD underperformed the Canadian Market which returned 15.7% over the past year.
Price Volatility
| GSD volatility | |
|---|---|
| GSD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.1% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CA Market | 17.2% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: GSD's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine GSD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Luc Gregoire | groupedevonian.com |
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name.
Devonian Health Group Inc. Fundamentals Summary
| GSD fundamental statistics | |
|---|---|
| Market cap | CA$28.16m |
| Earnings (TTM) | -CA$864.74k |
| Revenue (TTM) | CA$22.39m |
1.1x
P/S Ratio-27.4x
P/E RatioIs GSD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSD income statement (TTM) | |
|---|---|
| Revenue | CA$22.39m |
| Cost of Revenue | CA$15.21m |
| Gross Profit | CA$7.18m |
| Other Expenses | CA$8.04m |
| Earnings | -CA$864.74k |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | 32.06% |
| Net Profit Margin | -3.86% |
| Debt/Equity Ratio | 14.6% |
How did GSD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 23:24 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Devonian Health Group Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|